Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
$9.85
+4.7%
$12.24
$9.28
$14.63
$1.18B1.262.23 million shs4.46 million shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$106.38
+1.8%
$106.41
$77.43
$129.90
$2.05B0.87117,382 shs141,251 shs
MannKind Co. stock logo
MNKD
MannKind
$4.81
+5.5%
$4.88
$4.28
$7.63
$1.46B1.142.38 million shs2.57 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.26
+1.6%
$1.55
$1.19
$2.04
$999.25M1.423.89 million shs2.64 million shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
0.00%-16.95%-16.36%-28.71%-12.30%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
0.00%-4.49%+0.20%-8.45%+19.71%
MannKind Co. stock logo
MNKD
MannKind
0.00%-8.80%-2.15%-18.43%+5.56%
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.00%-9.39%-11.31%-23.94%-1.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
4.33 of 5 stars
3.32.00.04.72.51.71.9
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
4.4292 of 5 stars
3.50.00.04.43.92.51.9
MannKind Co. stock logo
MNKD
MannKind
3.0997 of 5 stars
3.62.00.00.03.50.81.9
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.5894 of 5 stars
3.43.00.04.42.55.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
2.50
Moderate Buy$24.00143.65% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.00
Buy$146.1437.38% Upside
MannKind Co. stock logo
MNKD
MannKind
3.25
Buy$10.00107.90% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.75
Moderate Buy$2.75118.25% Upside

Current Analyst Ratings Breakdown

Latest DVAX, LGND, MNKD, and OPK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.00
5/7/2025
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$33.00 ➝ $31.00
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
4/25/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
4/17/2025
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$12.00 ➝ $10.00
4/10/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$143.00
4/10/2025
MannKind Co. stock logo
MNKD
MannKind
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$12.00
4/9/2025
MannKind Co. stock logo
MNKD
MannKind
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/7/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/19/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/12/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
$294.62M4.01N/AN/A$4.81 per share2.05
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$181.49M11.30$4.36 per share24.39$40.39 per share2.63
MannKind Co. stock logo
MNKD
MannKind
$297.60M4.91N/AN/A($0.91) per share-5.29
OPKO Health, Inc. stock logo
OPK
OPKO Health
$689.41M1.45N/AN/A$1.80 per share0.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
-$6.39M-$0.5254.7220.10N/A9.85%4.22%2.67%N/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$52.15M-$7.1242.3828.67N/A29.68%4.95%4.39%N/A
MannKind Co. stock logo
MNKD
MannKind
-$11.94M$0.1068.7120.91N/A8.07%-17.74%8.68%N/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$188.86M-$0.07N/AN/AN/A-18.65%-9.76%-6.46%N/A

Latest DVAX, LGND, MNKD, and OPK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million
5/8/2025Q1 2025
MannKind Co. stock logo
MNKD
MannKind
$0.03$0.04+$0.01$0.04$75.86 million$78.35 million
5/6/2025Q1 2025
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
$0.03-$0.11-$0.14-$0.77$70.01 million$68.16 million
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
2/27/2025Q4 2024
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.08$0.01+$0.09$0.01$155.42 million$183.60 million
2/26/2025Q4 2024
MannKind Co. stock logo
MNKD
MannKind
$0.03$0.03N/A$0.03$74.99 million$76.78 million
2/20/2025Q4 2024
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
$0.05$0.05N/A$0.05$72.70 million$72.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
MannKind Co. stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
0.33
13.23
12.34
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/A
12.49
11.81
MannKind Co. stock logo
MNKD
MannKind
N/A
4.54
4.17
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.30
2.97
2.69

Institutional Ownership

CompanyInstitutional Ownership
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
96.96%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
91.28%
MannKind Co. stock logo
MNKD
MannKind
49.55%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%

Insider Ownership

CompanyInsider Ownership
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
2.98%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
5.90%
MannKind Co. stock logo
MNKD
MannKind
2.70%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
350120.08 million127.54 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8019.28 million17.78 millionOptionable
MannKind Co. stock logo
MNKD
MannKind
400303.85 million267.51 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
4,200793.05 million359.94 millionOptionable

Recent News About These Companies

Q1 2025 OPKO Health Inc Earnings Call
OPKO Health: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dynavax Technologies stock logo

Dynavax Technologies NASDAQ:DVAX

$9.85 +0.44 (+4.68%)
Closing price 04:00 PM Eastern
Extended Trading
$10.09 +0.24 (+2.44%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$106.38 +1.90 (+1.82%)
Closing price 04:00 PM Eastern
Extended Trading
$106.60 +0.23 (+0.21%)
As of 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

MannKind stock logo

MannKind NASDAQ:MNKD

$4.81 +0.25 (+5.48%)
Closing price 04:00 PM Eastern
Extended Trading
$4.70 -0.11 (-2.18%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.26 +0.02 (+1.61%)
Closing price 04:00 PM Eastern
Extended Trading
$1.26 0.00 (0.00%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.